Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY)
CUSIP: 75943R102
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 4,389,099
- Total 13F shares
- 130,456,510
- Share change
- +296,269
- Total reported value
- $1,097,122,997
- Put/Call ratio
- 69%
- Price per share
- $8.41
- Number of holders
- 169
- Value change
- -$2,918,566
- Number of buys
- 89
- Number of sells
- 57
Quarterly Holders Quick Answers
What is CUSIP 75943R102?
CUSIP 75943R102 identifies RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 75943R102:
Top shareholders of RLAY - Relay Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD |
13F
|
Company |
636%
|
27,904,963
|
$350,486,335 | — | 30 Jun 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
240%
|
10,528,567
|
$132,238,801 | — | 30 Jun 2023 | |
| BlackRock Finance, Inc. |
13F
|
Company |
191%
|
8,367,728
|
$105,098,663 | — | 30 Jun 2023 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
190%
|
8,345,517
|
$104,820,000 | — | 30 Jun 2023 | |
| STATE STREET CORP |
13F
|
Company |
164%
|
7,210,797
|
$90,567,610 | — | 30 Jun 2023 | |
| Casdin Capital, LLC |
13F
|
Company |
137%
|
5,998,574
|
$75,342,089 | — | 30 Jun 2023 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
114%
|
4,994,905
|
$62,736,007 | — | 30 Jun 2023 | |
| Bellevue Group AG |
13F
|
Company |
95%
|
4,170,800
|
$52,385,248 | — | 30 Jun 2023 | |
| EcoR1 Capital, LLC |
13F
|
Company |
95%
|
4,163,824
|
$52,297,629 | — | 30 Jun 2023 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
78%
|
3,418,669
|
$42,938,483 | — | 30 Jun 2023 | |
| BVF INC/IL |
13F
|
Company |
71%
|
3,120,521
|
$39,193,744 | — | 30 Jun 2023 | |
| FMR LLC |
13F
|
Company |
67%
|
2,956,221
|
$37,130,135 | — | 30 Jun 2023 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
52%
|
2,263,360
|
$28,428,000 | — | 30 Jun 2023 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
44%
|
1,943,097
|
$24,405,298 | — | 30 Jun 2023 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
43%
|
1,881,260
|
$23,628,633 | — | 30 Jun 2023 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
43%
|
1,871,030
|
$23,500,137 | — | 30 Jun 2023 | |
| Boxer Capital, LLC |
13F
|
Company |
41%
|
1,819,132
|
$22,848,000 | — | 30 Jun 2023 | |
| NORGES BANK |
13F
|
Company |
37%
|
1,613,784
|
$20,269,127 | — | 30 Jun 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
36%
|
1,574,157
|
$19,771,412 | — | 30 Jun 2023 | |
| Alphabet Inc. |
13F
|
Company |
36%
|
1,568,753
|
$19,703,537 | — | 30 Jun 2023 | |
| MPM BioImpact LLC |
13F
|
Company |
31%
|
1,354,368
|
$17,010,862 | — | 30 Jun 2023 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
29%
|
1,289,451
|
$16,195,504 | — | 30 Jun 2023 | |
| Artal Group S.A. |
13F
|
Company |
28%
|
1,213,725
|
$15,244,000 | — | 30 Jun 2023 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
27%
|
1,164,386
|
$14,625,712 | — | 30 Jun 2023 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
20%
|
886,542
|
$14,601,346 | — | 30 Jun 2023 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
26%
|
1,160,117
|
$14,571,070 | — | 30 Jun 2023 | |
| S.c.a. Candriam |
13F
|
Individual |
22%
|
971,070
|
$12,196,639 | — | 30 Jun 2023 | |
| Nextech Invest Ltd. |
13F
|
Company |
22%
|
948,659
|
$11,915,157 | — | 30 Jun 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
18%
|
794,228
|
$9,975,504 | — | 30 Jun 2023 | |
| MORGAN STANLEY |
13F
|
Company |
18%
|
777,467
|
$9,764,986 | — | 30 Jun 2023 | |
| Finepoint Capital LP |
13F
|
Company |
16%
|
701,570
|
$8,811,719 | — | 30 Jun 2023 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
16%
|
700,000
|
$8,792,000 | — | 30 Jun 2023 | |
| Rock Springs Capital Management LP |
13F
|
Company |
15%
|
673,966
|
$8,465,013 | — | 30 Jun 2023 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
15%
|
672,394
|
$8,445,269 | — | 30 Jun 2023 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
14%
|
627,013
|
$7,875,283 | — | 30 Jun 2023 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
14%
|
593,002
|
$7,448,105 | — | 30 Jun 2023 | |
| BESSEMER GROUP INC |
13F
|
Company |
13%
|
584,463
|
$7,341,000 | — | 30 Jun 2023 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
9.9%
|
434,209
|
$5,453,665 | — | 30 Jun 2023 | |
| BAILLIE GIFFORD & CO |
13F
|
Company |
9.4%
|
411,308
|
$5,166,029 | — | 30 Jun 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
8.6%
|
378,756
|
$4,757,175 | — | 30 Jun 2023 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
8.3%
|
363,883
|
$4,570,368 | — | 30 Jun 2023 | |
| Bank of New York Mellon Corp |
13F
|
Company |
7.3%
|
321,761
|
$4,041,319 | — | 30 Jun 2023 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
7.2%
|
317,969
|
$3,993,690 | — | 30 Jun 2023 | |
| BARCLAYS PLC |
13F
|
Company |
7%
|
309,179
|
$3,883,288 | — | 30 Jun 2023 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
7%
|
308,015
|
$3,868,668 | — | 30 Jun 2023 | |
| HARBOURVEST PARTNERS LLC |
13F
|
Company |
6.8%
|
296,402
|
$3,722,809 | — | 30 Jun 2023 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
6.3%
|
276,540
|
$3,473,339 | — | 30 Jun 2023 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
6%
|
263,507
|
$3,309,648 | — | 30 Jun 2023 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
5.9%
|
260,082
|
$3,266,630 | — | 30 Jun 2023 | |
| Woodline Partners LP |
13F
|
Company |
5.7%
|
250,000
|
$3,140,000 | — | 30 Jun 2023 |
Institutional Holders of Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) as of Q3 2023
As of 30 Sep 2023,
Relay Therapeutics, Inc. - Common Stock, $0.01 par value (RLAY) was held by
169 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
130,456,510 shares.
The largest 10 holders included
SB INVESTMENT ADVISERS (UK) LTD, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., Casdin Capital, LLC, JPMORGAN CHASE & CO, STATE STREET CORP, Bellevue Group AG, EcoR1 Capital, LLC, and ArrowMark Colorado Holdings LLC.
This page lists
169
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
159
Q3 2023 holders
169
Holder diff
10
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.